Structural and Expression Analysis of Salinity Stress Responsive
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Plenary and Platform Abstracts
American Society of Human Genetics 68th Annual Meeting PLENARY AND PLATFORM ABSTRACTS Abstract #'s Tuesday, October 16, 5:30-6:50 pm: 4. Featured Plenary Abstract Session I Hall C #1-#4 Wednesday, October 17, 9:00-10:00 am, Concurrent Platform Session A: 6. Variant Insights from Large Population Datasets Ballroom 20A #5-#8 7. GWAS in Combined Cancer Phenotypes Ballroom 20BC #9-#12 8. Genome-wide Epigenomics and Non-coding Variants Ballroom 20D #13-#16 9. Clonal Mosaicism in Cancer, Alzheimer's Disease, and Healthy Room 6A #17-#20 Tissue 10. Genetics of Behavioral Traits and Diseases Room 6B #21-#24 11. New Frontiers in Computational Genomics Room 6C #25-#28 12. Bone and Muscle: Identifying Causal Genes Room 6D #29-#32 13. Precision Medicine Initiatives: Outcomes and Lessons Learned Room 6E #33-#36 14. Environmental Exposures in Human Traits Room 6F #37-#40 Wednesday, October 17, 4:15-5:45 pm, Concurrent Platform Session B: 24. Variant Interpretation Practices and Resources Ballroom 20A #41-#46 25. Integrated Variant Analysis in Cancer Genomics Ballroom 20BC #47-#52 26. Gene Discovery and Functional Models of Neurological Disorders Ballroom 20D #53-#58 27. Whole Exome and Whole Genome Associations Room 6A #59-#64 28. Sequencing-based Diagnostics for Newborns and Infants Room 6B #65-#70 29. Omics Studies in Alzheimer's Disease Room 6C #71-#76 30. Cardiac, Valvular, and Vascular Disorders Room 6D #77-#82 31. Natural Selection and Human Phenotypes Room 6E #83-#88 32. Genetics of Cardiometabolic Traits Room 6F #89-#94 Wednesday, October 17, 6:00-7:00 pm, Concurrent Platform Session C: 33. -
Chuanxiong Rhizoma Compound on HIF-VEGF Pathway and Cerebral Ischemia-Reperfusion Injury’S Biological Network Based on Systematic Pharmacology
ORIGINAL RESEARCH published: 25 June 2021 doi: 10.3389/fphar.2021.601846 Exploring the Regulatory Mechanism of Hedysarum Multijugum Maxim.-Chuanxiong Rhizoma Compound on HIF-VEGF Pathway and Cerebral Ischemia-Reperfusion Injury’s Biological Network Based on Systematic Pharmacology Kailin Yang 1†, Liuting Zeng 1†, Anqi Ge 2†, Yi Chen 1†, Shanshan Wang 1†, Xiaofei Zhu 1,3† and Jinwen Ge 1,4* Edited by: 1 Takashi Sato, Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of 2 Tokyo University of Pharmacy and Life Cardio-Cerebral Diseases, Hunan University of Chinese Medicine, Changsha, China, Galactophore Department, The First 3 Sciences, Japan Hospital of Hunan University of Chinese Medicine, Changsha, China, School of Graduate, Central South University, Changsha, China, 4Shaoyang University, Shaoyang, China Reviewed by: Hui Zhao, Capital Medical University, China Background: Clinical research found that Hedysarum Multijugum Maxim.-Chuanxiong Maria Luisa Del Moral, fi University of Jaén, Spain Rhizoma Compound (HCC) has de nite curative effect on cerebral ischemic diseases, *Correspondence: such as ischemic stroke and cerebral ischemia-reperfusion injury (CIR). However, its Jinwen Ge mechanism for treating cerebral ischemia is still not fully explained. [email protected] †These authors share first authorship Methods: The traditional Chinese medicine related database were utilized to obtain the components of HCC. The Pharmmapper were used to predict HCC’s potential targets. Specialty section: The CIR genes were obtained from Genecards and OMIM and the protein-protein This article was submitted to interaction (PPI) data of HCC’s targets and IS genes were obtained from String Ethnopharmacology, a section of the journal database. -
Downloaded from the App Store and Nucleobase, Nucleotide and Nucleic Acid Metabolism 7 Google Play
Hoytema van Konijnenburg et al. Orphanet J Rare Dis (2021) 16:170 https://doi.org/10.1186/s13023-021-01727-2 REVIEW Open Access Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app Eva M. M. Hoytema van Konijnenburg1†, Saskia B. Wortmann2,3,4†, Marina J. Koelewijn2, Laura A. Tseng1,4, Roderick Houben6, Sylvia Stöckler‑Ipsiroglu5, Carlos R. Ferreira7 and Clara D. M. van Karnebeek1,2,4,8* Abstract Background: The Treatable ID App was created in 2012 as digital tool to improve early recognition and intervention for treatable inherited metabolic disorders (IMDs) presenting with global developmental delay and intellectual disabil‑ ity (collectively ‘treatable IDs’). Our aim is to update the 2012 review on treatable IDs and App to capture the advances made in the identifcation of new IMDs along with increased pathophysiological insights catalyzing therapeutic development and implementation. Methods: Two independent reviewers queried PubMed, OMIM and Orphanet databases to reassess all previously included disorders and therapies and to identify all reports on Treatable IDs published between 2012 and 2021. These were included if listed in the International Classifcation of IMDs (ICIMD) and presenting with ID as a major feature, and if published evidence for a therapeutic intervention improving ID primary and/or secondary outcomes is avail‑ able. Data on clinical symptoms, diagnostic testing, treatment strategies, efects on outcomes, and evidence levels were extracted and evaluated by the reviewers and external experts. The generated knowledge was translated into a diagnostic algorithm and updated version of the App with novel features. Results: Our review identifed 116 treatable IDs (139 genes), of which 44 newly identifed, belonging to 17 ICIMD categories. -
Gene Amplifications at Chromosome 7 of the Human Gastric Cancer Genome
225-231 4/7/07 20:50 Page 225 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 20: 225-231, 2007 225 Gene amplifications at chromosome 7 of the human gastric cancer genome SANGHWA YANG Cancer Metastasis Research Center, Yonsei University College of Medicine, 134 Shinchon-Dong, Seoul 120-752, Korea Received April 20, 2007; Accepted May 7, 2007 Abstract. Genetic aberrations at chromosome 7 are known to Introduction be related with diverse human diseases, including cancer and autism. In a number of cancer research areas involving gastric The completion of human genome sequencing and the cancer, several comparative genomic hybridization studies subsequent gene annotations, together with a rapid develop- employing metaphase chromosome or BAC clone micro- ment of high throughput screening technologies, such as DNA arrays have repeatedly identified human chromosome 7 microarrays, have made it possible to perform genome-scale as containing ‘regions of changes’ related with cancer expression profiling and comparative genomic hybridizations progression. cDNA microarray-based comparative genomic (CGHs) in various cancer models. The elucidation of gene hybridization can be used to directly identify individual target copy number variations in several cancer genomes is generating genes undergoing copy number variations. Copy number very informative results. Metaphase chromosome CGH and change analysis for 17,000 genes on a microarray format was the recent introduction of BAC and especially cDNA micro- performed with tumor and normal gastric tissues from 30 array-based CGHs (aCGH) (1) have greatly contributed to patients. A group of 90 genes undergoing copy number the identification of chromosome aberrations and of amplified increases (gene amplification) at the p11~p22 or q21~q36 and deleted genes in gastric cancer tissues and cell lines (2-9). -
Nonadditive Effects of Genes in Human Metabolomics
HIGHLIGHTED ARTICLE GENETICS | INVESTIGATION Nonadditive Effects of Genes in Human Metabolomics Yakov A. Tsepilov,*,†,‡,§,** So-Youn Shin,††,‡‡ Nicole Soranzo,††,§§ Tim D. Spector,*** Cornelia Prehn,††† Jerzy Adamski,†††,‡‡‡,§§§ Gabi Kastenmüller,***,**** Rui Wang-Sattler,§,** Konstantin Strauch,‡,†††† Christian Gieger,‡,**,§ Yurii S. Aulchenko,*,† and Janina S. Ried‡ *Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia, †Novosibirsk State University, 630090 Novosibirsk, Russia, ‡Institute of Genetic Epidemiology, §Research Unit of Molecular Epidemiology, **Institute of Epidemiology II, †††Institute of Experimental Genetics, Genome Analysis Center, and ****Institute of Bioinformatics and Systems Biology, Helmholtz Zentrum München–German Research Center for Environmental Health, 85764 Neuherberg, Germany, ††Human Genetics, Wellcome Trust Sanger Institute, Genome Campus, Hinxton, CB10 1HH, United Kingdom, ‡‡MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, BS8 1TH, United Kingdom, §§Department of Haematology, University of Cambridge, Cambridge, CB2 0AH, United Kingdom, ***Department of Twin Research and Genetic Epidemiology, King’s College London, London, WC2R 2LS, United Kingdom, ‡‡‡Institute of Experimental Genetics, Life and Food Science Center Weihenstephan, Technische Universität München, 85354 Freising-Weihenstephan, Germany, §§§German Center for Diabetes Research, 85764 Neuherberg, Germany, ††††Institute -
The First Insight Into the Genetic Structure of the Population Of
www.nature.com/scientificreports OPEN The frst insight into the genetic structure of the population of modern Serbia Tamara Drljaca1, Branka Zukic2, Vladimir Kovacevic3, Branislava Gemovic1, Kristel Klaassen‑Ljubicic2, Vladimir Perovic1, Mladen Lazarevic3, Sonja Pavlovic2* & Nevena Veljkovic1,4* The complete understanding of the genomic contribution to complex traits, diseases, and response to treatments, as well as genomic medicine application to the well‑being of all humans will be achieved through the global variome that encompasses fne‑scale genetic diversity. Despite signifcant eforts in recent years, uneven representation still characterizes genomic resources and among the underrepresented European populations are the Western Balkans including the Serbian population. Our research addresses this gap and presents the frst ever targeted sequencing dataset of variants in clinically relevant genes. By measuring population diferentiation and applying the Principal Component and Admixture analysis we demonstrated that the Serbian population difers little from other European populations, yet we identifed several novel and more frequent variants that appear as its unique genetic determinants. We explored thoroughly the functional impact of frequent variants and its correlation with the health burden of the population of Serbia based on a sample of 144 individuals. Our variants catalogue improves the understanding of genetics of modern Serbia, contributes to research on ancestry, and aids in improvements of well‑being and health equity. In addition, this resource may also be applicable in neighboring regions and valuable in worldwide functional analyses of genetic variants in individuals of European descent. In the era of high-throughput next generation sequencing (NGS) technology, the common goal for clinical use of sequencing data is the identifcation of pathogenic variants that can afect an individual’s health through link- ing genes and diseases1–3. -
Large-Scale Neuroanatomical Study Uncovers 198 Gene Associations in Mouse Brain Morphogenesis
ARTICLE https://doi.org/10.1038/s41467-019-11431-2 OPEN Large-scale neuroanatomical study uncovers 198 gene associations in mouse brain morphogenesis Stephan C. Collins1,2,3,4,5,12, Anna Mikhaleva6,12, Katarina Vrcelj7,12, Valerie E. Vancollie 8,12, Christel Wagner1,2,3,4, Nestor Demeure1,2,3,4, Helen Whitley1,2,3,4, Meghna Kannan 1,2,3,4, Rebecca Balz6, Lauren F.E. Anthony8, Andrew Edwards9,10, Hervé Moine1,2,3,4, Jacqueline K. White8, David J. Adams8, Alexandre Reymond6, Christopher J. Lelliott 8, Caleb Webber7,11 & Binnaz Yalcin 1,2,3,4,6 1234567890():,; Brain morphogenesis is an important process contributing to higher-order cognition, however our knowledge about its biological basis is largely incomplete. Here we analyze 118 neu- roanatomical parameters in 1,566 mutant mouse lines and identify 198 genes whose disruptions yield NeuroAnatomical Phenotypes (NAPs), mostly affecting structures impli- cated in brain connectivity. Groups of functionally similar NAP genes participate in pathways involving the cytoskeleton, the cell cycle and the synapse, display distinct fetal and postnatal brain expression dynamics and importantly, their disruption can yield convergent phenotypic patterns. 17% of human unique orthologues of mouse NAP genes are known loci for cognitive dysfunction. The remaining 83% constitute a vast pool of genes newly implicated in brain architecture, providing the largest study of mouse NAP genes and pathways. This offers a complementary resource to human genetic studies and predict that many more genes could be involved in mammalian brain morphogenesis. 1 Institut de Génétique et de Biologie Moléculaire et Cellulaire, 67404 Illkirch, France. -
Phosphoserine Phosphatase Is a Novel Prognostic Biomarker On
ANTICANCER RESEARCH 37 : 2365-2371 (2017) doi:10.21873/anticanres.11574 Phosphoserine Phosphatase Is a Novel Prognostic Biomarker on Chromosome 7 in Colorectal Cancer KUNIAKI SATO 1,2 , TAKAAKI MASUDA 1, QINGJIANG HU 1, TARO TOBO 3, SHINYA KIDOGAMI 1, YUSHI OGAWA 1, TOMOKO SAITO 1, SHO NAMBARA 1, HISATERU KOMATSU 1, HIDENARI HIRATA 1, SHOTARO SAKIMURA 1, RYUTARO UCHI 2, NAOKI HAYASHI 1, TOMOHIRO IGUCHI 1, HIDETOSHI EGUCHI 1, SHUHEI ITO 1, TAKASHI NAKAGAWA 2 and KOSHI MIMORI 1 Departments of 1Surgery and 3Clinical Laboratory Medicine and Pathology, Kyushu University Beppu Hospital, Oita, Japan; 2Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Abstract. Background/Aim: Amplification of chromosome 7p and cellular heterogeneity within a single tumor. ITH likely (Ch.7p) is common in colorectal cancer (CRC). The aim of contributes to the occurrence of drug-resistant cells and this study was to identify potential driver genes on Ch.7p that increases the chance of therapeutic failure, since the presence are overexpressed due to DNA copy number amplification and of distinct subpopulations of cells with different sensitivities determine their clinical significance in CRC. Materials and to anti-cancer drugs increases the chance of resistance and Methods: We identified phosphoserine phosphatase (PSPH) as recurrence (3). Therefore, it is important to identify a potential driver gene using a CRC dataset from The Cancer oncogenes that exist in tumor cells, as such oncogenes could Genome Atlas (TCGA) using a bioinformatics approach. The be promising therapeutic targets despite ITH. expression of PSPH in 124 primary CRCs was examined by Amplification of chromosome 7 occurs frequently in CRC quantitative reverse transcription polymerase chain reaction and colorectal adenoma tissues (4-6). -
Protein Interactions in the Cancer Proteome† Cite This: Mol
Molecular BioSystems View Article Online PAPER View Journal | View Issue Small-molecule binding sites to explore protein– protein interactions in the cancer proteome† Cite this: Mol. BioSyst., 2016, 12,3067 David Xu,ab Shadia I. Jalal,c George W. Sledge Jr.d and Samy O. Meroueh*aef The Cancer Genome Atlas (TCGA) offers an unprecedented opportunity to identify small-molecule binding sites on proteins with overexpressed mRNA levels that correlate with poor survival. Here, we analyze RNA-seq and clinical data for 10 tumor types to identify genes that are both overexpressed and correlate with patient survival. Protein products of these genes were scanned for binding sites that possess shape and physicochemical properties that can accommodate small-molecule probes or therapeutic agents (druggable). These binding sites were classified as enzyme active sites (ENZ), protein–protein interaction sites (PPI), or other sites whose function is unknown (OTH). Interestingly, the overwhelming majority of binding sites were classified as OTH. We find that ENZ, PPI, and OTH binding sites often occurred on the same structure suggesting that many of these OTH cavities can be used for allosteric modulation of Creative Commons Attribution 3.0 Unported Licence. enzyme activity or protein–protein interactions with small molecules. We discovered several ENZ (PYCR1, QPRT,andHSPA6)andPPI(CASC5, ZBTB32,andCSAD) binding sites on proteins that have been seldom explored in cancer. We also found proteins that have been extensively studied in cancer that have not been previously explored with small molecules that harbor ENZ (PKMYT1, STEAP3,andNNMT) and PPI (HNF4A, MEF2B,andCBX2) binding sites. All binding sites were classified by the signaling pathways to Received 29th March 2016, which the protein that harbors them belongs using KEGG. -
Large-Scale Neuroanatomical Study Uncovers 198 Gene Associations in Mouse Brain Morphogenesis
ARTICLE https://doi.org/10.1038/s41467-019-11431-2 OPEN Large-scale neuroanatomical study uncovers 198 gene associations in mouse brain morphogenesis Stephan C. Collins1,2,3,4,5,12, Anna Mikhaleva6,12, Katarina Vrcelj7,12, Valerie E. Vancollie 8,12, Christel Wagner1,2,3,4, Nestor Demeure1,2,3,4, Helen Whitley1,2,3,4, Meghna Kannan 1,2,3,4, Rebecca Balz6, Lauren F.E. Anthony8, Andrew Edwards9,10, Hervé Moine1,2,3,4, Jacqueline K. White8, David J. Adams8, Alexandre Reymond6, Christopher J. Lelliott 8, Caleb Webber7,11 & Binnaz Yalcin 1,2,3,4,6 1234567890():,; Brain morphogenesis is an important process contributing to higher-order cognition, however our knowledge about its biological basis is largely incomplete. Here we analyze 118 neu- roanatomical parameters in 1,566 mutant mouse lines and identify 198 genes whose disruptions yield NeuroAnatomical Phenotypes (NAPs), mostly affecting structures impli- cated in brain connectivity. Groups of functionally similar NAP genes participate in pathways involving the cytoskeleton, the cell cycle and the synapse, display distinct fetal and postnatal brain expression dynamics and importantly, their disruption can yield convergent phenotypic patterns. 17% of human unique orthologues of mouse NAP genes are known loci for cognitive dysfunction. The remaining 83% constitute a vast pool of genes newly implicated in brain architecture, providing the largest study of mouse NAP genes and pathways. This offers a complementary resource to human genetic studies and predict that many more genes could be involved in mammalian brain morphogenesis. 1 Institut de Génétique et de Biologie Moléculaire et Cellulaire, 67404 Illkirch, France. -
WO2012031008A2.Pdf
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau „ (10) International Publication Number (43) International Publication Date \ r / n n n A 8 March 2012 (08.03.2012) W / (51) International Patent Classification: (72) Inventors; and CI2Q 1/68 (2006.01) (75) Inventors/Applicants (for US only): BALAJ, Leonora [IT/US]; 9 Cedar Street, Charlestown, Massachusetts (21) International Application Number: 02129 (US). NOERHOLM, Mikkel [DK/DE]; PCT/US201 1/050041 Preysingstrasse 21, 8213 1 Gauting (DE). BREAKE- (22) International Filing Date: FIELD, Xandra O . [US/US]; 127 Homer Street, Newton, 31 August 201 1 (3 1.08.201 1) Massachusetts 02459 (US). (25) Filing Language: English (74) Agents: RESNICK, David S . et al; Nixon Peabody LLP, 100 Summer St., Boston, Massachusetts 021 10-21 3 1 (26) Publication Langi English (US). (30) Priority Data: (81) Designated States (unless otherwise indicated, for every 61/378,860 31 August 2010 (3 1.08.2010) US kind of national protection available): AE, AG, AL, AM, 61/421,421 9 December 2010 (09.12.2010) US AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, 61/437,547 28 January 201 1 (28.01 .201 1) us CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 61/438,1 99 31 January 201 1 (3 1.01 .201 1) us DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 61/493,261 3 June 201 1 (03.06.201 1) us HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (71) Applicant (for all designated States except US): THE KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, GENERAL HOSPITAL CORPORATION [US/US]; ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 55 Fruit Street, Boston, Massachusetts 021 14 (US). -
Disease Model Discovery from 3,328 Gene Knockouts by the International Mouse Phenotyping Consortium
HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nat Genet Manuscript Author . Author manuscript; Manuscript Author available in PMC 2017 December 26. Published in final edited form as: Nat Genet. 2017 August ; 49(8): 1231–1238. doi:10.1038/ng.3901. Disease Model Discovery from 3,328 Gene Knockouts by The International Mouse Phenotyping Consortium A full list of authors and affiliations appears at the end of the article. Abstract Although next generation sequencing has revolutionised the ability to associate variants with human diseases, diagnostic rates and development of new therapies are still limited by our lack of knowledge of function and pathobiological mechanism for most genes. To address this challenge, the International Mouse Phenotyping Consortium (IMPC) is creating a genome- and phenome- wide catalogue of gene function by characterizing new knockout mouse strains across diverse biological systems through a broad set of standardised phenotyping tests, with all mice made readily available to the biomedical community. Analysing the first 3328 genes reveals models for 360 diseases including the first for type C Bernard-Soulier, Bardet-Biedl-5 and Gordon Holmes syndromes. 90% of our phenotype annotations are novel, providing the first functional evidence for 1092 genes and candidates in unsolved diseases such as Arrhythmogenic Right Ventricular Dysplasia 3. Finally, we describe our role in variant functional validation with the 100,000 Genomes and other projects. INTRODUCTION With its extensive toolkit for genome modification and capacity for recapitulating human disease, the laboratory mouse is arguably the preferred model organism for studying and validating the effect of genetic variants in Mendelian disease, as well as identifying previously unsuspected disease genes.